Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Secukinumab - Novartis

Next Previous
Drug Profile

Secukinumab - Novartis

Alternative Names: AIN-457; Anti-interleukin 17A monoclonal antibody; Cosentyx; KB-03303A; Kosentikusu; NVP-AIN-457; Scapho

Latest Information Update: 23 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon; Novartis
  • Developer Beth Israel Deaconess Medical Center; GWT-TUD GmbH; Icahn School of Medicine at Mount Sinai; Novartis
  • Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-radiographic axial spondyloarthritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Hidradenitis suppurativa; Non-radiographic axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Registered Juvenile rheumatoid arthritis
  • Phase III Giant cell arteritis; Graves ophthalmopathy; Polymyalgia rheumatica
  • Phase II Atopic dermatitis; Discoid lupus erythematosus; Necrobiosis lipoidica; SARS-CoV-2 acute respiratory disease; Tendon injuries
  • Discontinued Alopecia areata; Asthma; Crohn's disease; Dry eyes; Lichen planus; Lupus nephritis; Multiple sclerosis; Rheumatoid arthritis; Rotator cuff injuries; Type 1 diabetes mellitus; Uveitis

Most Recent Events

  • 02 Apr 2025 Novartis Pharmaceuticals completes a phase I trial in Polymyalgia rheumatica and Giant cell arteritis in USA, Czech Republic, Italy, Portugal, Spain, Switzerland (IV)(NCT06130540)
  • 04 Mar 2025 Discontinued - Phase-III for Rotator-cuff-injuries (In adults, Treatment-resistant) in Germany (SC)
  • 04 Mar 2025 Discontinued - Phase-III for Rotator-cuff-injuries (Treatment-resistant) in Argentina (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top